| |
|---|
| Generic name | Bremelanotide |
| Research name | PT-141 |
| Brand name | Vyleesi |
| Compound type | Synthetic cyclic peptide |
| Length | 7 amino acids |
| Drug class | Melanocortin receptor agonist |
| Main research area | Sexual desire and arousal |
| Primary proposed receptors | MC3R and MC4R |
| FDA approval | Yes, for a restricted HSDD indication |
| Approved UK medicine | No |
| Approved for men | No |
| Approved for sexual performance enhancement | No |
The FDA approved Vyleesi on 21 June 2019 for acquired, generalised hypoactive sexual desire disorder in selected premenopausal women.
What is PT-141?
PT-141 is the research-development name commonly used for bremelanotide.
Bremelanotide is a synthetic cyclic peptide derived from research involving the melanocortin system.
Its cyclic structure means that part of the peptide forms a ring.
Cyclisation can affect:
Bremelanotide activates several melanocortin receptors, with its effects on sexual behaviour believed to involve primarily the MC3 and MC4 receptors within the central nervous system.
What is bremelanotide?
Bremelanotide is the formal generic name for PT-141.
The two names refer to the same active compound, although commercial research products labelled PT-141 should not automatically be assumed to match the purity, formulation or concentration of an approved bremelanotide medicine.
The FDA-approved product is supplied as a prefilled subcutaneous autoinjector containing 1.75 mg in 0.3 mL.
This does not mean that unregulated PT-141 products are medically equivalent to Vyleesi.
How was PT-141 developed?
PT-141 was developed from research involving melanotan II, another synthetic melanocortin peptide.
Melanotan II was initially investigated for its effects on skin pigmentation.
During early research, investigators observed unexpected sexual responses, including spontaneous erections in some male participants.
This led researchers to isolate and develop a related compound intended to retain sexual-response effects while reducing pigmentation-related activity.
That compound became PT-141, or bremelanotide.
What is the melanocortin system?
The melanocortin system is a network of peptides and receptors involved in numerous biological functions.
These include:
Naturally occurring melanocortins are produced from the precursor protein:
Pro-opiomelanocortin, or POMC
POMC-derived peptides include:
ACTH
Alpha-MSH
Beta-MSH
Gamma-MSH
These peptides act through five known melanocortin receptors:
Bremelanotide does not activate all these receptors equally.
Which receptors does PT-141 activate?
Bremelanotide is described as a non-selective melanocortin receptor agonist.
It has activity at several melanocortin receptors but does not meaningfully activate MC2R, the ACTH receptor responsible for stimulating adrenal cortisol production.
Its sexual effects are believed to involve mainly:
These receptors are expressed in brain regions involved in:
Sexual motivation
Reproductive behaviour
Autonomic responses
Reward processing
Appetite regulation
The complete mechanism behind bremelanotide’s clinical effects has not been fully established.
PT-141 and MC4R
MC4R is widely expressed within the central nervous system.
It plays established roles in:
Appetite
Energy expenditure
Body-weight regulation
Autonomic signalling
Sexual behaviour
Activation of MC4R is thought to contribute to bremelanotide’s effects on sexual desire and arousal.
However, MC4R activation can also influence blood pressure and other autonomic functions, which helps explain some of the medicine’s safety concerns.
PT-141 and MC3R
MC3R is involved in energy balance, metabolic regulation and neural signalling.
Its precise role in human sexual behaviour is less clearly defined than that of MC4R.
Animal experiments suggest that both MC3R and MC4R pathways may contribute to melanocortin-related sexual responses.
It remains difficult to assign bremelanotide’s clinical effects to one receptor alone.
Does PT-141 increase dopamine?
Bremelanotide does not act as a conventional dopamine agonist.
However, melanocortin receptor activation may influence downstream dopamine pathways involved in:
Motivation
Reward
Sexual interest
Behavioural activation
FDA chemistry-review documents describe a proposed mechanism in which MC4R activation influences hypothalamic dopamine activity and sexual desire.
This remains a simplified model rather than a complete explanation of its effects.
Is PT-141 a hormone?
No.
PT-141 is a synthetic peptide and melanocortin receptor agonist.
It does not directly replace:
Testosterone
Oestrogen
Progesterone
Oxytocin
Dopamine
It may influence brain pathways associated with sexual response without substantially increasing sex-hormone concentrations.
PT-141 and sexual desire
Bremelanotide was specifically developed to influence sexual desire rather than simply improve genital blood flow.
Human trials have measured outcomes including:
Sexual desire
Distress related to low desire
Sexual arousal
Frequency of satisfying sexual events
Patient-reported treatment benefit
Two phase III trials, known collectively as the RECONNECT studies, reported statistically significant improvements in sexual desire and reductions in distress associated with low desire in premenopausal women with HSDD.
The size and clinical importance of the average benefit have nevertheless been debated. One clinical review described the overall clinical benefit as potentially modest, while later methodological critiques questioned aspects of the trial outcome measures.
What is hypoactive sexual desire disorder?
Hypoactive sexual desire disorder, or HSDD, describes persistently reduced sexual desire that causes significant personal distress.
A diagnosis requires more than simply having a lower libido than a partner or experiencing normal fluctuations in sexual interest.
Low desire should not be better explained by:
Another medical condition
A psychiatric condition
Relationship difficulties
Medication effects
Substance use
Temporary stress
Pregnancy or postpartum changes
Bremelanotide’s US indication is specifically limited to acquired, generalised HSDD in premenopausal women whose symptoms are not caused by these other factors.
What does acquired HSDD mean?
“Acquired” means the low desire developed after a previous period of satisfactory sexual desire.
It does not refer to someone who has experienced low desire throughout their entire sexual life.
What does generalised HSDD mean?
“Generalised” means the low desire occurs:
It is not limited to one relationship, situation or type of stimulation.
FDA approval
The FDA approved Vyleesi in June 2019.
The approved indication is:
Acquired, generalised HSDD in premenopausal women whose low sexual desire causes marked distress or interpersonal difficulty and is not caused by a medical or psychiatric condition, relationship problems, medication or drug use.
The FDA label specifically states that it is not indicated:
Is PT-141 approved in the UK?
Bremelanotide is not an authorised medicine in the United Kingdom.
It should therefore not be described on a UK research website as an approved libido treatment.
FDA approval in the United States does not automatically provide:
MHRA approval
UK prescribing authorisation
UK marketing authorisation
Approval for unlicensed commercial PT-141 products
PT-141 clinical trials in women
The RECONNECT clinical programme included two similarly designed phase III trials.
Participants were premenopausal women with acquired, generalised HSDD.
The studies compared bremelanotide with placebo over approximately 24 weeks.
The co-primary outcomes evaluated:
The trials reported statistically significant improvement in both measures.
However, the increase in satisfying sexual events did not form the basis of the FDA-approved efficacy conclusion, and the average magnitude of benefit was not dramatic.
The most scientifically balanced conclusion is that bremelanotide produced a measurable benefit for some women, but responses varied and the average effect was modest.
Long-term evidence
Participants from the phase III trials could enter a 52-week open-label extension.
The extension reported sustained symptom improvements and no new major safety signal.
However, open-label studies have important limitations because:
Participants know they are receiving the active treatment.
There may be no continuing placebo comparison.
People who did not tolerate or benefit from treatment may be more likely to withdraw.
Expectation can influence subjective outcomes.
The extension was funded by companies involved in bremelanotide’s development.
Does PT-141 increase satisfying sexual events?
The phase III trials did not demonstrate a strong improvement in every sexual outcome measured.
This distinction matters because:
Desire scores may improve without more frequent sexual activity.
Reduced distress is not identical to increased arousal.
Improved arousal is not identical to orgasm.
Clinical benefit may differ considerably between individuals.
Bremelanotide should not be described as guaranteeing increased sexual activity or satisfaction.
PT-141 and female sexual arousal
Earlier phase II research included women with HSDD and female sexual arousal disorder.
Some studies reported improvements in patient-reported desire and arousal measures.
However, the eventual FDA indication was limited to HSDD rather than every form of female sexual dysfunction.
Female sexual difficulties may result from:
Menopause
Vaginal dryness
Pelvic pain
Endometriosis
Medication
Trauma
Relationship distress
Depression
Hormonal changes
Neurological disease
A central desire-targeting medicine may not address these underlying causes.
PT-141 and low libido in postmenopausal women
The FDA-approved indication does not include postmenopausal women.
Low desire after menopause may involve:
Evidence for bremelanotide in this population remains insufficient for an approved indication.
PT-141 and men
PT-141 has been investigated experimentally in men, particularly in relation to erectile responses.
However, it is not FDA approved for men.
Male sexual dysfunction may involve:
Vascular disease
Diabetes
Low testosterone
Neurological disease
Medication
Anxiety
Relationship factors
Pelvic surgery
Sleep disorders
PT-141 should not be presented as a proven general treatment for male sexual dysfunction.
PT-141 and erections
Melanocortin receptor activation may produce erectile responses through central nervous-system pathways.
This differs from phosphodiesterase-5 inhibitors, which act largely by increasing blood flow within erectile tissue.
Early studies of melanocortin compounds reported spontaneous erections in some men.
Bremelanotide has therefore been investigated for erectile dysfunction, including in people with an inadequate response to sildenafil.
However, the evidence was not sufficient to obtain approval for male erectile dysfunction.
PT-141 vs sildenafil
PT-141 and sildenafil act through different pathways.
| PT-141 / Bremelanotide | Sildenafil |
|---|
| Primary action | Central melanocortin signalling | Peripheral PDE5 inhibition |
| Main target | Desire and central arousal pathways | Penile blood flow |
| Approved for men | No | Yes |
| Requires sexual stimulation | Effects remain context dependent | Generally yes |
| Blood-pressure concern | Temporary increases | Potential decreases, especially with nitrates |
| UK authorisation | No | Approved sildenafil medicines exist |
They are not interchangeable.
PT-141 and tadalafil
Tadalafil is another PDE5 inhibitor used for erectile dysfunction.
Like sildenafil, it acts primarily on vascular signalling rather than directly increasing sexual desire.
There is insufficient high-quality evidence establishing the safety and effectiveness of combining tadalafil with unregulated PT-141 products.
Does PT-141 increase testosterone?
Bremelanotide is not established as a testosterone-raising treatment.
Its main effects appear to occur through central melanocortin pathways rather than by stimulating the hypothalamic–pituitary–gonadal axis.
It should not be used as a substitute for investigating:
Low testosterone
Pituitary disease
Testicular disease
Hyperprolactinaemia
Thyroid disorders
Does PT-141 increase oestrogen?
There is no established clinically significant oestrogen-raising effect.
Its approved use does not depend on directly replacing or increasing oestrogen.
PT-141 and orgasm
PT-141 is sometimes promoted as an orgasm-enhancing peptide.
Clinical trials focused primarily on sexual desire and distress.
Although improved desire or arousal could indirectly affect orgasm for some individuals, bremelanotide has not been proven to guarantee:
Faster orgasm
Stronger orgasm
Multiple orgasms
Resolution of anorgasmia
Difficulty reaching orgasm may have distinct neurological, medication-related, hormonal or psychological causes.
PT-141 and antidepressant-related sexual dysfunction
SSRIs and other antidepressants may cause:
The FDA indication specifically excludes low desire caused by a medication or drug substance.
Evidence is insufficient to establish PT-141 as a standard treatment for antidepressant-induced sexual dysfunction.
Changing psychiatric medication without medical supervision may cause relapse or withdrawal symptoms.
PT-141 and menopause
PT-141 does not replace oestrogen or treat the broader symptoms of menopause.
It would not be expected to directly correct:
Low desire caused by painful sex or vaginal dryness may require a different treatment approach.
PT-141 and relationship-related low desire
The approved indication excludes low desire caused primarily by relationship difficulties.
Sexual desire is influenced by:
A pharmacological treatment may not resolve these factors.
PT-141 and sexual-performance enhancement
Bremelanotide is not approved to improve sexual performance in people without a diagnosed sexual-desire disorder.
The FDA label explicitly excludes general performance enhancement.
Claims that PT-141 reliably increases performance in healthy men or women go beyond the approved evidence.
How is bremelanotide administered clinically?
The FDA-approved product is administered by subcutaneous injection.
It is intended for use when needed rather than as a daily medicine.
The authorised US product has specific limits on:
These prescribing instructions apply to the approved medicine and should not be converted into instructions for unregulated research products.
Why is dosing frequency limited?
Bremelanotide can cause temporary increases in blood pressure and reductions in heart rate.
Frequent exposure also increases the cumulative risk of focal hyperpigmentation.
The FDA label therefore limits repeated use and advises discontinuation when meaningful benefit is not achieved.
Blood-pressure effects
Bremelanotide can temporarily increase blood pressure.
The increase usually occurs after administration and later returns towards baseline.
Because of this effect, the approved product is contraindicated in people with:
The FDA concluded that blood-pressure risks could be addressed through product labelling rather than a formal risk-management programme.
This cardiovascular warning is one of the most important distinctions between controlled medical use and informal peptide use.
PT-141 and heart rate
A temporary reduction in heart rate may accompany the rise in blood pressure.
The interaction between blood pressure, heart rate and autonomic signalling may vary between individuals.
People with cardiovascular disease were not the intended population for general unsupervised exposure.
Nausea
Nausea is the most commonly reported adverse effect of bremelanotide.
In the phase III programme, nausea was frequent and was one of the main reasons some participants discontinued treatment.
Nausea may be accompanied by:
Vomiting
Headache
Flushing
Reduced appetite
Dizziness
The development programme included further investigation into nausea and the use of anti-nausea medication.
Hyperpigmentation
Bremelanotide can cause darkening of the skin.
Reported areas include:
This is known as focal hyperpigmentation.
The risk appears greater with repeated exposure and in people with darker skin pigmentation.
Some pigmentation changes may not fully resolve after treatment is stopped.
This effect is biologically plausible because melanocortin receptors are also involved in pigment regulation.
Headache and flushing
Commonly reported adverse reactions include:
Headache
Flushing
Injection-site reactions
Vomiting
Cough
Fatigue
Dizziness
Nasal symptoms
Most trial adverse events were described as mild or moderate, but tolerability varied.
Serious adverse effects
The clinical programme did not identify a large rate of serious drug-related adverse events.
However, this does not mean that all PT-141 exposure is low risk.
Safety concerns may increase when:
Product identity is uncertain.
Concentration is inaccurate.
Cardiovascular screening is absent.
Doses are repeated frequently.
Multiple sexual-function drugs are combined.
The compound is used in populations not included in trials.
PT-141 and cardiovascular disease
Bremelanotide is not appropriate for people with established cardiovascular disease under its FDA label.
Potentially relevant conditions include:
Sexual activity itself can also place temporary demands on the cardiovascular system.
PT-141 and blood-pressure medication
There is insufficient evidence to assume that blood-pressure medication completely removes bremelanotide’s cardiovascular risk.
Bremelanotide may also slow gastric emptying and could affect the absorption of certain oral medicines.
People taking cardiovascular medication require individual clinical assessment.
Delayed gastric emptying
Bremelanotide may slow gastric emptying.
This can potentially alter the rate at which some oral medicines are absorbed.
This is particularly important for medicines that require:
The interaction may be clinically important even when the peptide does not directly alter the medicine’s metabolism.
PT-141 and oral contraceptives
Because bremelanotide may delay gastric emptying, there is a theoretical possibility of altered absorption of oral medicines.
The significance for any particular oral contraceptive depends on the formulation and timing.
There is insufficient evidence to give universal reassurance about unregulated PT-141 use alongside oral contraception.
PT-141 and alcohol
A phase I study evaluated bremelanotide with ethanol and did not identify a major new serious safety signal under the controlled conditions studied.
This does not prove that combining PT-141 with alcohol is always safe.
Alcohol may independently affect:
Blood pressure
Judgement
Sexual decision-making
Nausea
Dehydration
Consent
Erectile function
PT-141 and sildenafil combination
Because the compounds act through different pathways, researchers and commercial users have shown interest in combining them.
However, robust clinical evidence establishing the safety of combining unregulated PT-141 with sildenafil is limited.
Potential concerns include:
Blood-pressure changes
Headache
Flushing
Dizziness
Nausea
Cardiovascular stress
Priapism
Combination use should not be described as established or risk-free.
Priapism risk
Priapism is an erection lasting several hours that does not resolve normally.
It can damage erectile tissue and requires urgent treatment.
Although bremelanotide is not a conventional direct vasodilator, prolonged erections are a possible concern when compounds affecting sexual response are used, particularly in combination.
An erection lasting four hours requires emergency medical assessment.
PT-141 and pregnancy
Bremelanotide is not intended for use during pregnancy.
Its clinical purpose is unrelated to pregnancy, and animal reproductive data have raised concerns about fetal harm at certain exposures.
People who may become pregnant require appropriate medical guidance.
Naturally occurring melanocortin signalling does not prove that externally administered bremelanotide is safe during pregnancy.
PT-141 and breastfeeding
There is insufficient evidence to establish safety during breastfeeding.
It is uncertain whether bremelanotide or biologically active metabolites pass into human milk.
PT-141 and fertility
Bremelanotide is not a fertility treatment.
Increasing sexual desire does not necessarily improve:
Ovulation
Sperm production
Egg quality
Implantation
Pregnancy rates
Live-birth rates
Low desire and infertility are separate clinical issues, although they may sometimes coexist.
PT-141 and cancer
There is no established evidence that PT-141 treats cancer.
Because melanocortin receptors are expressed in several tissues and influence diverse biological pathways, long-term effects in people with active cancer remain insufficiently characterised.
Pigmentation changes should also not automatically be assumed to be harmless without appropriate assessment.
PT-141 and mental health
Sexual desire is closely linked with:
Depression
Anxiety
Trauma
Body image
Medication
Relationship health
Stress
Bremelanotide was not approved for low desire primarily caused by a psychiatric condition.
A treatment that modifies desire does not resolve the underlying mental-health disorder.
Does PT-141 cause compulsive sexual behaviour?
Compulsive sexual behaviour was not established as a common adverse effect in the clinical programme.
However, any centrally acting substance that influences reward or motivation raises reasonable questions about behavioural responses.
Long-term evidence in populations with:
is limited.
PT-141 vs flibanserin
Flibanserin is another medicine approved in the United States for selected women with HSDD.
| Bremelanotide | Flibanserin |
|---|
| Type | Melanocortin peptide agonist | Non-peptide serotonergic medicine |
| Use pattern | As needed | Daily |
| Route | Subcutaneous injection | Oral tablet |
| Primary concern | Nausea, blood pressure, pigmentation | Hypotension, sedation and interactions |
| US indication | Selected premenopausal women with HSDD | Selected women with HSDD under current US labelling |
| UK authorisation | No | No routine UK authorisation |
They have different mechanisms and safety profiles.
Is PT-141 a recreational aphrodisiac?
The word aphrodisiac is often used commercially but is scientifically imprecise.
Bremelanotide has demonstrated effects on sexual-desire measures in a specific clinical population.
This does not establish it as a safe recreational enhancer for people without HSDD.
Product-quality concerns
A commercial vial labelled PT-141 may differ substantially from FDA-approved bremelanotide.
Important variables include:
Correct peptide identity
Cyclic structure
Peptide purity
Concentration
Sterility
Endotoxin content
Counterions
Degradation
Storage
Reconstitution quality
A purity result alone does not establish:
Analytical testing
